Search PubMed⌕ Search

Biomedical subjects

A Osman

Publications and source records attributed to A Osman.

112 records · Page 7Linked to original sources
PubMedDate not supplied

A study of the absorptive function of the small intestine in childhood malignant lymphomas.

A study of the absorptive function of the small intestine in chidlhood malignant lymphomas was carried out at the Cancer Institute of Cairo University. The study comprised twenty-five children, with stage III or IV lymphoma. A complete lymphoma work-up was performed for each patient, comprising clinical, pathological, haematological, biochemical and roentgenological assessments. Evaluation of small intestinal function was done by means of mucosal biopsy, small bowel motor meal, xylose excretion test, and estimation of faecal fat excretion. These tests revealed evidence of malabsorption in 69% of the patients. The study provides a better understanding of childhood malignant lymphomas in Egypt, and shows that malabsorption may be more common in the disease than has been previously suspected.

Adolescent↗
PubMedDate not supplied

Alphafetoprotein in screening for congenital hypothyroidism.

This study was conducted on 500 full-term neonates and 25 older patients with congenital hypothyroidism (CH), newly or previously diagnosed. Alphafetoprotein (AFP) was elevated in two neonates. In one, persistent elevation of AFP and thyroid stimulating hormone (TSH) with low thyroxine (T4) were found (congenital hypothyroidism). In the other, AFP, TSH and T4 levels normalized (transient hypothyroidism). The mean AFP level in new CH patients was significantly higher than in previously diagnosed patients, and was higher in CH patients than in controls. Significant relationships were found between AFP and T4, AFP and TSH, and AFP and age. AFP is a sensitive indicator of thyroid status and can be used as a screening test for hypothyroidism from the first day of life and in follow-up of CH patients.

Adolescent↗
PubMedDate not supplied

Chemotherapeutic management of bronchogenic carcinoma: trials with NSC-140117, a new methanesulfonic acid ester of aminoglycol.

A new drug, NSC-140117, was used in the management of 15 patients who had late bronchogenic carcinoma and were unable to receive surgical or radiotherapeutic treatment. Good responses in the form of 90% shrinkage in the size of the lesionswere encountered in nine patients (60%). Response is still being maintained from 6 months to 1.5 years after the start of therapy. No toxic effects, including hematopoietic toxicity, were encountered.

Adult↗